Unlock instant, AI-driven research and patent intelligence for your innovation.

Compounds, compositions and methods of inhibiting alpha-synuclein toxicity

A technology for synuclein and toxicity, which can be used in drug combinations, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc., and can solve problems such as the ambiguous relationship between synuclein pathology and neurodegenerative diseases

Inactive Publication Date: 2007-10-24
WHITEHEAD INST FOR BIOMEDICAL RES +1
View PDF56 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, mutations in the α-synuclein gene were identified, which, although extremely rare in familial Parkinson's disease, also illustrate the ambiguous relationship between synuclein pathology and neurodegenerative disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
  • Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
  • Compounds, compositions and methods of inhibiting alpha-synuclein toxicity

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0304] C. Preparation of compounds

[0305] The compounds described for use in the compositions and methods provided herein are available from commercial sources (eg, Aldrich Chemical Co., Milwaukee, WI), can be prepared by methods well known to those skilled in the art or as shown herein. One skilled in the art should be able to prepare all of the compounds used herein by routine modification of the above methods using appropriate starting materials.

[0306] Some of the compounds provided herein can be prepared by the synthetic routes shown below. Briefly, aryl or heteroaryl amines are converted to 1 using the corresponding nitrile. Compound 1 can also be synthesized in other ways, including starting from aryl halides or heteroaryl halides, using the corresponding guanidinium salts. Treatment of compound 1 with an acid halide or anhydride affords the corresponding acylated compound 2, which can be converted to the corresponding amide 3 by reaction with ammonia. Compound 1...

Embodiment 1

[0406] α-Synuclein (aS) Screening

[0407] yeast strain

[0408] Parent W303: MAT a / α ade2-1 / ade2-1 his3-11, 15 / his3-11, 15 leu2-3, 112 / leu2-3, 112

[0409] trp1-1 / trp1-1 ura3-1 / ura3-1 can1-100 / can1-100

[0410] Phenotype: Requires adenine, histidine, leucine, tryptophan, and uracil for growth. Resistant to canavanine.

[0411] Fx-109: MAT a / α ade2-1 / ade2-1 his3-11, 15 / his3-11, 15leu2-3, 112 / leu2-3, 112

[0412] trp1-1 / trp1-1 GALp-aS-GFP::TRP1 / GALp-aS-GFP::TRP1 ura3-1 / ura3-1

[0413] GALp-aS-GFP::URA3 / GALp-aS-GFP::URA3 can1-100 / can1-100pdr1::KanMX / pdr1::KanMX erg6::KanMX / erg6::KanMX

[0414] Phenotype: Inability to grow on galactose due to expression of aS. Requires histidine, leucine, and adenine for growth. Resistant to canavanine and kanamycin. Highly sensitive to drugs.

[0415] Media and Reagents

[0416] Depending on the genotype of the strain to be tested, select appropriate supplements for the synthetic media. Strains containing an integrating construct (eg ...

Embodiment 2

[0435] Some compounds according to formulas I-IX can be prepared as follows.

[0436] Preparation of guanidine

[0437] method 1

[0438]

[0439] The mixture of guanidine carbonate (22g, 120mmol) and 2-chlorobenzoxazole (7ml, 60mmol) in N, N-diisopropylethylamine (45ml, 259mmol) and DMF (100ml) solution was at 60°C Heat overnight. After evaporation it was treated with water (100ml). The ppts were collected, washed with ether and dried. Yield of desired intermediate product: 9.3 g (88%), beige solid. Purity: 95%.

[0440] Method 2

[0441]

[0442] Mix 2-aminobenzothiazole 1 (1eq) and 2-methyl-2-thiopseudourea sulfate (2-methyl-2-thiopseudourea sulfate) (1eq) in a vial, in an oil above the melting point of the mixture Bath (140-220 ° C) was heated with stirring for 2h. After cooling the mixture was triturated well with hot MeOH, filtered and washed with MeOH. The resulting gray solid product (presumably in the mixed sulfate form with the S-methyl-2-thiopseudoure...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of a-synuclein toxicity, a-synuclein mediated diseases or diseases in which a-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihydropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application Serial No. 60 / 610,796, filed September 17, 2004, which is hereby incorporated by reference in its entirety. [0003] Statement Regarding Federally Sponsored Research [0004] Funding to support portions of the research disclosed herein was provided through grant number NIH NS 44829 awarded by the National Institutes of Health. The government may have certain rights in this invention. field of invention [0005] The subject matter provided herein relates to compounds, compositions and methods that inhibit alpha-synuclein toxicity. In one embodiment, the compound is benzothiazolyl, benzoxazolyl and benzimidazolylguanidine, benzimidazolylhydrazone, benzodihydropyridone, dihydropyridone, thienylstilbene Ketones and N-benzimidazolyl-aminopyrazoles. In another embodiment, the compounds are used in a method of treating an alpha-synuclei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/425A61K31/42A61K31/415A61K31/44
CPCA61K31/522A61P25/00A61P25/16A61P25/28
Inventor 苏珊·L·林德奎斯特蒂亚高·奥泰罗理查德·拉鲍迪尼尔
Owner WHITEHEAD INST FOR BIOMEDICAL RES